- Home
- CRBP vs MNTK Comparison
CRBP vs MNTK Comparison
Compare CRBP & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | MNTK |
|---|---|---|
| Founded | 2009 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 202.0M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRBP | MNTK |
|---|---|---|
| Price | $9.27 | $1.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $45.50 | $1.80 |
| AVG Volume (30 Days) | ★ 467.9K | 192.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,822,272.00 | ★ $176,382,000.00 |
| Revenue This Year | N/A | $18.55 |
| Revenue Next Year | $116.00 | $12.68 |
| P/E Ratio | ★ N/A | $146.00 |
| Revenue Growth | ★ 97.62 | 0.37 |
| 52 Week Low | $7.12 | $1.07 |
| 52 Week High | $20.56 | $2.66 |
Technical Indicators
Market Signals| Indicator | CRBP | MNTK |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 57.09 |
| Support Level | $7.42 | $1.59 |
| Resistance Level | $9.57 | $1.72 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | 0.21 | -0.00 |
| Stochastic Oscillator | 87.14 | 83.02 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.